Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alfuzosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | GLA | P06280 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | ACHE | P22303 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfuzosin SCHEMBL29355511 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL34477 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL2950056 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL29497289 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL30690015 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL2851348 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL4744369 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL29492949 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL179910 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL4745192 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087367-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | ACCELERON PHARMA INC. | 2020-03-19 | — | — | US | disclosed |
| CN-110603049-A | Compositions and methods for treating heart failure | 阿塞勒隆制药公司 | 2019-12-20 | — | — | CN | disclosed |
| WO-2018144968-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | ACCELERON PHARMA INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| US-9821017-B2 | Extract of Asplenium nidus L | JIN XIN BIOTECHNOLOGY CO., LTD. (TW) | 2017-11-21 | — | — | US | disclosed |
| US-20170266251-A1 | HERBAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND RELATED DISORDERS | SEIPEL TRACEY ANNE (AU) | 2017-09-21 | — | — | US | disclosed |
| US-9682115-B2 | Herbal compositions for the prevention or treatment of benign prostatic hyperplasia and related disorders | Seipel Group Pty Ltd (AU) | 2017-06-20 | — | — | US | disclosed |
| CN-103505457-B | Application of stachys sieboldii extract | 景鑫生物科技有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-106398676-A | Temperature-resistant and salt-resistant thick oil emulsifying viscosity reducer and application thereof | 大连百奥泰科技有限公司 | 2017-02-15 | — | — | CN | disclosed |
| US-9359197-B2 | Method of diagnosing, prognosing and monitoring parkinson's disease | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2016-06-07 | — | — | US | disclosed |
| EP-3015105-A1 | ASPLENIUM NIDUS EXTRACT AND USE THEREOF | Jin Xin Biotechnology Co. Ltd. (TW) | 2016-05-04 | — | — | EP | disclosed |
| WO-2005112538-A2 | USE OF ADRENERGIC N-PHENYLPIPERAZINE ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHODS OF PREPARING THEM. | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRJ (BR) | 2005-12-01 | — | — | WO | disclosed |
| EP-1592430-A2 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ENERGOLYTIC AGENTS | Threshold Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005068414-A1 | CATALYTIC HYDROGENATION OF NITRILES TO PRODUCE CAPSAICINOID DERIVATIVES AND AMINE COMPOUNDS, AND METHODS FOR PURIFIYING AND OBTAINING THE POLYMORPHS THEREOF | STIEFEL LABORATORIES, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-1556014-A1 | SUSTAINED RELEASE COMPOSITIONS CONTAINING ALFUZOSIN | RANBAXY LABORATORIES, LTD. (IN) | 2005-07-27 | — | — | EP | disclosed |
| US-20050108053-A1 | Interactive internet medical pharmaceutical prescribing system | JONES MILES J JR (US) | 2005-05-19 | — | — | US | disclosed |
| CN-1583029-A | Medicine for prostate hyperplasia and its preparation | HEKANG PHARMACEUTICAL CO LTD C (CN) | 2005-02-23 | — | — | CN | disclosed |
| US-20040167196-A1 | Treatment of benign prostatic hyperplasia | THRESHOLD PHARMACEUTICALS, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004064736-A2 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ENERGOLYTIC AGENTS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004064735-A2 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004037228-A1 | SUSTAINED RELEASE COMPOSITIONS CONTAINING ALFUZOSIN | RANBAXY LABORATORIES LIMITED (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087367-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | BMPR2, BMPR1B, BMP1 | ADRA1D 1990/4885ADRA1A 2043/4885ADRA1B 981/4885 |
| US-20040167196-A1 | Treatment of benign prostatic hyperplasia | BPHL, LPXN, QDPR | ADRA1D 415/4885ADRA1A 314/4885ADRA1B 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.